Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | $17.15 |
| 52 Week Low | $7.05 |
| Target Price | $28.00 |
| Ticker | BNTC:UW |
| Composite Ticker | BNTC:US |
| Security Name | Benitec Biopharma Inc |
| Type | Ordinary Shares |
| Class | BNTC |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | Equity |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG00RZSWZ16 |
| Composite FIGI | BBG00R712L56 |
| Share Class FIGI | BBG00R712L65 |
| FIGI Unique ID | N/A |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | 2023-07-26 |
| Beta | 0.7106 |
| 1-year beta | 0.15 |
| 3-year beta | 0.7106 |
| 5-year beta | 1.0682 |
| 7-year beta | 0.9551 |
| 10-year beta | 0.8526 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
